Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference, taking place May 23rd-25th, 2022.

UBS Global Healthcare Conference fireside chat details:

Date:   Monday, May 23rd, 2022
Time:   1:15pm Eastern Time 
Webcast:   The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, we are boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. Our investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit


Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.

Primary Logo

Source: Immunovant